The FDA granted orphan-drug designation to ImmunoGen's lorvotuzumab mertasine as a treatment for small-cell lung cancer. The treatment previously obtained orphan-drug status for Merkel cell carcinoma in the U.S. and Europe.
Published in Brief:
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.
|Assistant Vice President - Dental Director||